Skip to main content

Tempest Therapeutics, Inc. (TPST)

NASDAQ: TPST · IEX Real-Time Price · USD
13.72 -0.19 (-1.33%)
Oct 21, 2021 11:39 AM EDT - Market open
Market Cap93.18M
Revenue (ttm)n/a
Net Income (ttm)-29.18M
Shares Out925,432
EPS (ttm)-20.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,324
Open13.72
Previous Close13.90
Day's Range13.50 - 14.10
52-Week Range10.39 - 41.55
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 9, 2021

About TPST

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is hea...

IndustryBiotechnology
Founded2011
CEOJulia Owens
Employees14
Stock ExchangeNASDAQ
Ticker SymbolTPST
Full Company Profile

Financial Performance

Financial Statements

News

Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combin...

2 weeks ago - GlobeNewsWire

Tempest to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combi...

1 month ago - GlobeNewsWire

Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights

Closed merger transaction resulting in public listing (TPST)

2 months ago - GlobeNewsWire

H.C. Wainwright Says Targeted Oncology Therapies "Gives An Edge" To Tempest Therapeutics

H.C. Wainwright has initiated coverage of Tempest Therapeutics Inc (NASDAQ: TPST) with a Buy rating and $51 price target, seeing an upside potential of over 100%.  A strategic portfolio of targeted ther...

3 months ago - Benzinga

What's Going On With Tempest Therapeutics Stock?

Shares of the South San Francisco-based micro-cap biopharma Tempest Therapeutics Inc. (NASDAQ: TPST) were soaring Monday for a second consecutive trading session on above-average volume. Tempest's Wild ...

3 months ago - Benzinga

TPST Stock: 13 Things to Know About Tempest Therapeutics as Shares Skyrocket Post-Merger

Tempest Therapeutics (TPST) stock is rocketing higher on Monday and reaching new highs since its merger with Millendo Therapeutics. The post TPST Stock: 13 Things to Know About Tempest Therapeutics as S...

3 months ago - InvestorPlace

Tempest to Participate in William Blair 2021 Biotech Focus Conference

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combin...

3 months ago - GlobeNewsWire

Tempest Announces Appointment of Christine Pellizzari to its Board of Directors

SOUTH SAN FRANCISCO, July 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that co...

3 months ago - GlobeNewsWire

Tempest Closes Merger with Millendo and Completes PIPE Financing

SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics...

3 months ago - GlobeNewsWire

Tempest and Millendo Announce Stockholder Approval of Merger

Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST” Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST”

3 months ago - GlobeNewsWire

SHAREHOLDER ALERT: WeissLaw LLP Investigates Millendo Therapeutics, Inc.

NEW YORK, April 27, 2021 /PRNewswire/ -- If you own Millendo shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: ht...

5 months ago - PRNewsWire

MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Mi...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Millendo Therape...

6 months ago - Business Wire

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Millendo Therapeutics, Inc. - MLND

NEW YORK, April 2, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A...

6 months ago - PRNewsWire

Millendo Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Millendo Therapeut...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Millendo Therapeutics, Inc. (NASDAQ: MLND) and Tempest Therapeutics, Inc. is fair t...

6 months ago - Business Wire

Tempest Therapeutics To Go Public Via Millendo Therapeutics Merger

Millendo Therapeutics Inc (NASDAQ: MLND) has agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction. The combined company will operate under the Tempest Therapeutics mo...

6 months ago - Benzinga

Tempest and Millendo Announce Proposed Merger Agreement

SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics and Tempest Therapeutics announce a proposed merger agreement.

6 months ago - Business Wire

Millendo Therapeutics Provides Pipeline and Business Update

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces updates on its pipeline and business, including its Phase 1 study of MLE-301 for the treatment of vasomotor symptoms.

9 months ago - Business Wire

Millendo Therapeutics Reports Third Quarter 2020 Operating and Financial Results

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces operating and financial results for the quarter ended September 30, 2020.

11 months ago - Business Wire

3 Net Net Working Capital Stocks to Have a Look At

There are some investors who buy stocks that are trading below their liquidation value because they believe they can achieve impressive gains from their investments after the market has reassessed the s...

Other symbols:CGAUTSI
1 year ago - GuruFocus

Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with sig...

1 year ago - Business Wire

Millendo Therapeutics to Participate in September Investor Conferences

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Participate in September Investor Conferences

1 year ago - Business Wire

Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

1 year ago - Business Wire

Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

1 year ago - Business Wire

Is the Options Market Predicting a Spike in Millendo (MLND) Stock?

Investors need to pay close attention to Millendo (MLND) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Will Millendo Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Millendo Therapeutics.

1 year ago - Zacks Investment Research